Litcius/Paper detail

Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality

Feng Zhou, Ye-Mao Liu, Jing Xie, Haomiao Li, Fang Lei, Huilin Yang, Juan‐Juan Qin, Jingjing Cai, Xiao-Jing Zhang, Bin Wu, Xia Meng, Xiang Da, Chengzhang Yang, Xinliang Ma, Qingbo Xu, Zhigang Lu, Haofeng Lu, Xigang Xia, Daihong Wang, Xiaofeng Liao, Gang Peng, Jun Yang, Xiaodong Huang, Bing-Hong Zhang, Yufeng Yuan, Wei Xiang, Peter P. Liu, Yibin Wang, Peng Zhang, Zhi‐Gang She, Jiahong Xia, Hongliang Li

2020Hypertension65 citationsDOI

Topics & Concepts

Angiotensin Receptor BlockersAngiotensin-converting enzymeInternal medicineAngiotensin IIAngiotensin-converting enzyme 2MedicineCoronavirus disease 2019 (COVID-19)ReceptorBlood pressureInfectious disease (medical specialty)DiseaseCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchCOVID-19 and Mental Health
Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality | Litcius